Results 71 to 80 of about 934,005 (172)

Risk of Cancer With Hormone Replacement Therapy: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Hormone replacement therapy (HRT) remains the cornerstone of menopausal symptom management, effectively alleviating vasomotor symptoms and genitourinary syndrome, whilst mitigating long‐term risks such as osteoporosis. However, despite an increasing body of evidence on the relative safety of HRT, earlier studies that demonstrated an increased ...
Gabriella Yongue, Zachary Nash, Vikram Talaulikar, Shibani Nicum   +3 more
wiley   +1 more source

Gold‐standard evidence and best practice guidance for menstrual cycle‐informed clinical care: An overview for clinicians

British Journal of Clinical Psychology, EarlyView.
Abstract Objectives To synthesize current evidence and provide clinically actionable recommendations for integrating menstrual cycle‐related processes—particularly hormone sensitivity, Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Exacerbation (PME)—into psychological assessment, formulation and treatment.
Ellen R. Lambert, Louise N. Nolan, Katja M. Schmalenberger   +2 more
wiley   +1 more source

Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial

Trials, 2018
Background Progress in vitrification techniques has allowed reproductive physicians to consider new strategies for using progestin as an alternative to a GnRH analogue to improve in vitro fertilisation (IVF).
Yun Wang, Yanping Kuang, Qiuju Chen, Renfei Cai   +3 more
doaj   +1 more source

Progestin-Primed Ovarian Stimulation Protocol for Patients in Assisted Reproductive Technology: A Meta-Analysis of Randomized Controlled Trials

Frontiers in Endocrinology, 2021
ObjectivesProgestin-primed ovarian stimulation (PPOS) is a new ovarian stimulation protocol that can block the luteinizing hormone (LH) surge through progesterone instead of traditional down regulating or gonadotropin-releasing hormone (GnRH) antagonist,
Shaogen Guan, Yuezhi Feng, Yonghan Huang, Jia Huang   +3 more
doaj   +1 more source

Comparable Pregnancy Loss and Neonatal Birthweights in Frozen Embryo Transfer Cycles Using Vitrified Embryos from Progestin-Primed Ovarian Stimulation and GnRH Analogue Protocols: A Retrospective Cohort Study

, 2022
Background: The potential correlation between progestin-primed ovarian stimulation (PPOS) and the risk of compromised embryo competence still lacks sound evidence. Methods: A large retrospective cohort study was used to compare the incidence of pregnancy
Chen, Qiuju, Feng, Guang’en, Shi, Wentao, Guang’en Feng, Wentao Shi, Qiuju Chen, Yun Wang, Mengjie Wei, Weiran Chai, Chai, Weiran, Wang, Yun, Liao, Maokun, Maokun Liao, Wei, Mengjie   +13 more
core   +1 more source

ESHRE guideline: ovarian stimulation for IVF/ICSI† [PDF]

, 2020
What is the recommended management of ovarian stimulation, based on the best available evidence in the ...
Urbancsek, Janos, La Marca, Antonio, Bosch, Ernesto, Kunicki, Michal, Vermeulen, Nathalie, Lainas, George, Griesinger, Georg, Broekmans, Frank, Mastenbroek, Sebastiaan, Timeva, Tanya, Humaidan, Peter, Ovarian Stimulation, The Eshre Guideline Group On, Grynberg, Michael, Kolibianakis, Estratios, Polyzos, Nikolaos, Broer, Simone, Massin, Nathalie, Sunkara, Sesh Kamal, Le Clef, Nathalie, Töyli, Mira, MS VPG/Gynaecologie, Circulatory Health, Child Health   +22 more
core   +1 more source

Progesterone does not modulate myofibrillar protein synthesis at rest or following acute resistance exercise in premenopausal females

The Journal of Physiology, EarlyView.
Abstract figure legend Twenty premenopausal females in the early follicular phase (days 1–5) were randomised, double‐blind, to two 400 mg oral doses of micronized progesterone or matched placebo, taken 34 and 10 h before a primed continuous l‐[ring‐13C6]‐phenylalanine infusion beginning at t = −240 min. Bilateral vastus lateralis biopsies were obtained
Alysha C. D'Souza, Alison K. Shea, Caroline B. Dunlop, Matthew J. Lees, Hafsa Ali, Dax Houtkamp, Joel L. Prowting, James P. Newbold, Stuart M. Phillips   +8 more
wiley   +1 more source

Image_1_The Comparison of Fixed and Flexible Progestin Primed Ovarian Stimulation on Mature Oocyte Yield in Women at Risk of Premature Ovarian Insufficiency.tiff

, 2022
While gonadotrophin releasing hormone (GnRH) antagonists have been the standard of pituitary suppression during ovarian stimulation for ART, progestin primed ovarian stimulation (PPOS) has emerged as an alternative.
Sule Yildiz (12036809), Engin Turkgeldi (12036806), Ipek Keles (12036812), Erkan Kalafat (6207248), Merve Dizdar (12036803), Baris Ata (5810324)   +5 more
core   +1 more source

Comparison Between PPOS and GnRHa-Long Protocol in Clinical Outcome with the First IVF/ICSI Cycle: A Randomized Clinical Trial

Clinical Epidemiology, 2020
Qianwen Xi, Yu Tao, Meiting Qiu, Yun Wang, Yanping Kuang Department of Assisted Reproduction, Shanghai Ninth People’s Hospital Affiliated to JiaoTong University School of Medicine, Shanghai, People’s Republic of ChinaCorrespondence: Yun Wang;
Xi Q, Tao Y, Qiu M, Wang Y, Kuang Y
doaj  

Progestin-primed ovarian stimulation improves the outcomes of IVF/ICSI cycles in infertile women with diminished ovarian reserve

Journal of the Chinese Medical Association, 2019
Ovarian stimulation with clomiphene (CC) or progestin has been applied for patients with diminished ovarian reserve (DOR). However, it remains unclear which treatment confers greater benefits. This study aimed to compare the outcomes of progestin-primed ovarian stimulation (PPOS) protocol vs CC-primed ovarian stimulation (CPOS) in infertile women with ...
Chun-Mei, Yu, Xiu-Liang, Dai, Yu-Feng, Wang, Ting-Ting, Gao, Fang, Cao, Xi-Yang, Xia, Li, Chen   +6 more
openaire   +3 more sources